OOIR: Observatory of International Research

Papers

(The H4-Index of Clinical Pharmacology & Therapeutics is 36. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Issue Information	366
Return to SENDer: The Submitted Electronic Data for Nonclinical Cardiovascular Studies is Not Facilitating Transparency, Translation or Innovation	289
Exploring the Association Between Intra‐Patient Variability in Trough Concentration of Pazopanib and Clinical Outcomes in Renal Cell Carcinoma and Soft Tissue Sarcoma Patients	272
Machine Learning‐Led Optimization of Combination Therapy: Confronting the Public Health Threat of Extensively Drug Resistant Gram‐Negative Bacteria	227
In this Issue	132
ASCPT News	114
In This Issue	100
Estimating Culprit Drugs for Adverse Drug Reactions Based on Bayesian Inference	92
	85
French‐Speaking Network of Pharmacogenetics (RNPGx) Recommendations for Clinical Use of Mavacamten	81
FDA Adverse Event Reporting System Essentials: A Reflection on Study Conception	65
Correction to: Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Healthy Volunteers and Patients with Chronic Kidney Disease	64
Comprehensive Evaluation of OATP‐ and BCRP‐Mediated Drug–Drug Interactions of Methotrexate Using Physiologically‐Based Pharmacokinetic Modeling	63
A Randomized Trial Comparing Standard of Care to Bayesian Warfarin Dose Individualization	63
US Food and Drug Administration's Advancing Real‐World Evidence Program: Initial Experience	57
Nicotine Metabolite Ratio Decreases After Switching Off Efavirenz‐Based Therapy in People With HIV Who Smoke	56
Opportunities and Challenges of Disease Progression Modeling in Drug Development – An IQ Perspective	55
Methodological Insights on Biomarker‐Based Patient Selection: A Review of Scientific Advice Procedures at the European Medicines Agency	55
The Broader Context of Liquid Biopsy in Absorption, Distribution, Metabolism, and Elimination	51
Longitudinal Model‐Based Meta‐Analysis of Lung Function Response to Support Phase III Study Design in Chinese Patients With Asthma	51
Neurodegenerative Diseases: The Value of Early Predictive End Points	51
Progress in Clinical Pharmacology in China: A Randomized Controlled Study to Advance Genotype‐Guided Precision Medicine	50
Protecting the Kidney: The Unexpected Logic of Inhibiting a Glucose Transporter	49
Reply to “Interpretation of Pharmacovigilance Disproportionality Analyses”	47
Integrated Evidence Planning for Enhancing Patient Care: Harnessing the Power of Real‐World Evidence	46

Model‐Informed Selection of the Recommended Phase 2 Dosage for Anti‐TIGIT Immunotherapy Leveraging co‐Expressed PD‐1 Inhibitor Target Engagement	46
Reply to “Questioning Bayesian Inference‐Based Models for Estimating Culprit Drugs for Adverse Drug Reactions”	46
Model‐Based Prediction of Irinotecan‐Induced Grade 4 Neutropenia in Advanced Cancer Patients: Influence of Demographic and Clinical Factors	45
Liquid Biopsies or Therapeutic Drug Monitoring for CYP Activity Profile Determination	44
How to Successfully Generate an Alternative Approach to a Thorough QT Study: GLPG1972 as an Example	43
Drug‐Induced QT Prolongation: Associations Between Risk Classifications in a Swedish Clinical Decision Support System and Clinical Outcomes	42
Promoting Clinical Trial Diversity: A Highlight of Select US FDA Initiatives	41
Promise of Quantitative Proteomics in the Qualification of New Approach Methodologies	40
The Efficacy, Effectiveness, and Efficiency of Integrated QTc Assessment: Rationalizing Approaches to New Drug Modalities	40
More Than Pharmacokinetics: Transporters in Clinical Pharmacology	38
Repurposing Acebutolol for Osteoporosis Treatment: Insights From Multi‐Omics and Multi‐Modal Data Analysis	38
Predicting Survival in Patients with Advanced NSCLC Treated with Atezolizumab Using Pre‐ and on‐Treatment Prognostic Biomarkers	36
Repeated Intake of Grapefruit Juice Inhibits CYP2B6 , CYP2C9 , CYP2C19	36
Development of Therapeutic Proteins for a New Subcutaneous Route of Administration After the Establishment of Intravenous Dosages: A Systematic Review	36
Factors Influencing Medication Adherence in Heart Failure Patients—A Survey Among Cardiac Healthcare Providers	36
Effect of CYP3A5 and CYP3A4 Genetic Variants on Fentanyl Pharmacokinetics in a Pediatric Population	36